Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making. AGO is comprised of gynecological ...

We have learned more this week about how former President Trump would govern if reelected. Wednesday in Wisconsin, he again ...

Agendia Inc, headquartered in Irvine, California with a state-of-the-art laboratory facility, has announced that the company’s 80-gene molecular subtyping assay, BluePrint, is now included in the ...

The US Food and Drug Administration (FDA) has approved a new genetic test that could help patients with early-stage breast cancer predict their chance of relapse within 5 or 10 years, information ...

Guidelines now include both of Agendia’s genomic assays, MammaPrint ® and BluePrint ® IRVINE, Calif. & AMSTERDAM, April 11, 2024--(BUSINESS WIRE)--Agendia ®, Inc. announced today that the ...

MammaPrint was originally developed at The Netherlands Cancer Institute in Amsterdam using the Rosetta Inpharmatics DNA microarray system (Merck and Co., NJ, USA) and then commercialized on the ...

We acknowledge the financial support of Applied Biosystems, Agendia BV, the March of Dimes and the Juvenile Diabetes Research Foundation, which made it possible for the content to be freely available.

With institutional review board approval and Health Insurance Portability and Accountability Act (HIPPA) compliance, a multidisciplinary clinical and research data warehouse (RDW) expert group curated ...